Suppr超能文献

白蛋白尿、肾功能受损与老年人的心血管结局或死亡率。

Albuminuria, impaired kidney function and cardiovascular outcomes or mortality in the elderly.

机构信息

Tufts Medical Center and Tufts University School of Medicine, University of Washington, Seattle, USA.

出版信息

Nephrol Dial Transplant. 2010 May;25(5):1560-7. doi: 10.1093/ndt/gfp646. Epub 2009 Dec 15.

Abstract

BACKGROUND

Kidney disease is a risk factor for mortality and cardiovascular disease in older adults, but the separate and combined effects of albuminuria and cystatin C, a novel marker of glomerular filtration, are not known.

METHODS

We examined associations of these markers with mortality and cardiovascular outcomes during a median follow-up of 8.3 years in 3291 older adults in the Cardiovascular Health Study. Kidney disease was assessed using urinary albumin/creatinine ratio (ACR), cystatin C and Modification of Diet in Renal Disease estimated glomerular filtration rate (eGFR). We defined subgroups based on presence of microalbuminuria (MA, ACR > 30 mg/g) and categories of normal kidney function (cystatin C < 1.0 mg/L and eGFR > 60 mL/min/1.73 m(2)); preclinical kidney disease (cystatin C level > 1.0 mg/l but eGFR > 60 mL/min/1.73 m(2)); and chronic kidney disease (CKD) (eGFR < 60 mL/min/1.73 m(2)). Cox proportional hazards models were used to examine associations between these six subgroups and all-cause or cardiovascular mortality, myocardial infarction and heart failure.

RESULTS

One thousand one hundred fifty (34.9%) had normal kidney function (12.2% with MA), 1518 (46.1%) had preclinical kidney disease (17.9% with MA) and 622 (18.9%) had CKD (47% with MA). After adjustment, the presence of either preclinical kidney disease or MA was associated with an over 50% increase in mortality risk; the presence of both was associated with a 2.4-fold mortality risk. Those with CKD and MA were at highest risk, with a nearly 4-fold mortality risk.

CONCLUSION

Elevated cystatin C and albuminuria are common, identify different subsets of the older population, and are independent, graded risk factors for cardiovascular disease and mortality.

摘要

背景

肾脏疾病是老年人死亡和心血管疾病的一个风险因素,但白蛋白尿和半胱氨酸蛋白酶抑制剂 C(一种新的肾小球滤过标志物)的单独和联合作用尚不清楚。

方法

我们在心血管健康研究中对 3291 名老年人进行了中位随访 8.3 年的研究,检测了这些标志物与死亡率和心血管结局之间的关系。使用尿白蛋白/肌酐比值(ACR)、半胱氨酸蛋白酶抑制剂 C 和肾脏病饮食改良试验估计肾小球滤过率(eGFR)来评估肾脏疾病。我们根据是否存在微量白蛋白尿(ACR>30mg/g)和正常肾功能(半胱氨酸蛋白酶 C<1.0mg/L 和 eGFR>60mL/min/1.73m2)、亚临床肾脏疾病(半胱氨酸蛋白酶 C 水平>1.0mg/L 但 eGFR>60mL/min/1.73m2)和慢性肾脏病(eGFR<60mL/min/1.73m2)定义亚组。使用 Cox 比例风险模型来研究这六个亚组与全因或心血管死亡率、心肌梗死和心力衰竭之间的关系。

结果

1150 人(34.9%)具有正常肾功能(12.2%有微量白蛋白尿),1518 人(46.1%)有亚临床肾脏疾病(17.9%有微量白蛋白尿),622 人(18.9%)有慢性肾脏病(47%有微量白蛋白尿)。调整后,亚临床肾脏疾病或微量白蛋白尿的存在与死亡率风险增加 50%以上相关;两者同时存在与死亡率风险增加 2.4 倍相关。同时患有慢性肾脏病和微量白蛋白尿的人风险最高,死亡率风险几乎增加了 4 倍。

结论

半胱氨酸蛋白酶 C 和白蛋白尿的升高很常见,可识别老年人的不同亚组,且为独立的、分级的心血管疾病和死亡率危险因素。

相似文献

1
Albuminuria, impaired kidney function and cardiovascular outcomes or mortality in the elderly.
Nephrol Dial Transplant. 2010 May;25(5):1560-7. doi: 10.1093/ndt/gfp646. Epub 2009 Dec 15.
2
Kidney Function as Risk Factor and Predictor of Cardiovascular Outcomes and Mortality Among Older Adults.
Am J Kidney Dis. 2021 Mar;77(3):386-396.e1. doi: 10.1053/j.ajkd.2020.09.015. Epub 2020 Nov 14.
4
Combined association of creatinine, albuminuria, and cystatin C with all-cause mortality and cardiovascular and kidney outcomes.
Clin J Am Soc Nephrol. 2013 Mar;8(3):434-42. doi: 10.2215/CJN.04960512. Epub 2012 Dec 20.
8
CKD and cardiovascular disease in the Atherosclerosis Risk in Communities (ARIC) study: interactions with age, sex, and race.
Am J Kidney Dis. 2013 Oct;62(4):691-702. doi: 10.1053/j.ajkd.2013.04.010. Epub 2013 Jun 13.
10
Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease.
Ann Intern Med. 2006 Aug 15;145(4):237-46. doi: 10.7326/0003-4819-145-4-200608150-00003.

引用本文的文献

2
Using Risk Assessment to Improve Screening for Albuminuria among US Adults without Diabetes.
J Gen Intern Med. 2024 Nov 18. doi: 10.1007/s11606-024-09185-9.
4
Serum cystatin C and stroke risk: a national cohort and Mendelian randomization study.
Front Endocrinol (Lausanne). 2024 Apr 12;15:1355948. doi: 10.3389/fendo.2024.1355948. eCollection 2024.
6
Diagnostic value and utility of commonly used biomarkers of cardiac and renal function in cardiorenal syndromes: a narrative review.
Biochem Med (Zagreb). 2023 Oct 15;33(3):030502. doi: 10.11613/BM.2023.030502. Epub 2023 Aug 5.
7
Chronic Kidney Disease, Heart Failure, and Adverse Cardiac Remodeling in Older Adults: The ARIC Study.
JACC Heart Fail. 2023 May;11(5):523-537. doi: 10.1016/j.jchf.2023.01.029. Epub 2023 Apr 12.
8
High-Density Lipoprotein Lipidomics in Chronic Kidney Disease.
Clin Chem. 2023 Mar 1;69(3):273-282. doi: 10.1093/clinchem/hvac216.

本文引用的文献

1
Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population.
Am J Epidemiol. 2008 May 15;167(10):1226-34. doi: 10.1093/aje/kwn033. Epub 2008 Apr 2.
5
Prevalence of chronic kidney disease in the United States.
JAMA. 2007 Nov 7;298(17):2038-47. doi: 10.1001/jama.298.17.2038.
7
Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease.
Ann Intern Med. 2006 Aug 15;145(4):237-46. doi: 10.7326/0003-4819-145-4-200608150-00003.
8
Relation of microalbuminuria and coronary artery disease in patients with and without diabetes mellitus.
Am J Cardiol. 2006 Aug 1;98(3):279-81. doi: 10.1016/j.amjcard.2006.01.098. Epub 2006 Jun 6.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验